离子导入巩膜交联术对近视模型力学性能及胶原代谢的影响  

The Effects of Iontophoresis-Assisted Cross-Linking on Biomechanical Properties and Collagen Metabolism of Myopic Rabbit Sclera

作　　者：容烁 王超英[2] 韩宝雁 冯鹏飞[1] 兰伟伟 李晓娜[1] 陈维毅[1] 

机构地区：[1]太原理工大学应用力学与生物医学工程研究所,太原030024 [2]白求恩国际和平医院眼科,石家庄050082

出　　处：《太原理工大学学报》2017年第6期1000-1006,共7页Journal of Taiyuan University of Technology

基　　金：国家自然科学基金资助项目(31271005;11402162)

摘　　要：巩膜胶原交联术是有望控制近视病程发展的方法之一。然而,该术式的确切程序及其对近视动物模型的影响仍有待探讨。将离子导入法引入巩膜核黄素-紫外线A(UVA)交联术,采用10mW/cm^2,9min的快速交联方案,研究该术式对于近视动物模型巩膜生物力学性能及胶原代谢的影响。利用形觉剥夺法将96只新西兰大白兔诱导形成相对稳定的近视模型,然后进行巩膜交联术或假手术,术后4个时间点(1d,10d,1个月,3个月)分别采集样本和获取数据。术后4个时间点,与非交联近视眼相比,交联近视眼巩膜的极限应力、杨氏模量和生理杨氏模量均明显增加。此外,交联组与未交联组胶原代谢相关基因和蛋白的表达存在显著的差异。结果表明,离子导入核黄素-紫外线A快速交联术很可能是一种控制近视病理过程的可行性方法。Scleral collagen cross-linking(SXL)is one of the most promising treatments to control the pathologic process of myopia.The exact procedure and effects on myopic animal models still need to be explored.We applied an iontophoresis-assisted delivery system to the riboflavin/ultraviolet A(UVA)SXL procedure,and conducted an accelerated UVA irradiation(10 mW/cm^2,9 minutes)on a myopic animal model to explore the effects on scleral biomechanical properties and collagen metabolism.By form deprivation,ninety-six New Zealand white rabbits developed relatively stable myopia and then underwent the SXL surgery or sham-operation.All the sample and statistics were obtained from 4 time points(1-day,10-day,1-month and 3-month)after the surgery.The results show that the ultimate stress,Young's modulus and physiological Young's modulus of treated myopic sclera were significantly increased compared with those of untreated ones in all four groups.In addition,there were significant differences in the expression of genes and proteins related to collagen metabolism between the treated sclera samples and untreated ones.It demonstrated that iontophoresis-assisted accelerated Riboflavin/UVA SXL might be a potential method to control the pathological process of myopia.

关 键 词：巩膜交联 近视模型 离子导入 生物力学性能 基因及蛋白表达 核黄素-紫外线A 

分 类 号：R318.01[医药卫生—生物医学工程]